Skip to content

Study · Animal study (in vivo) · duck · 2005

2 results

[Combination of lamivudine with thymosin alpha1 in treatment of duck hepatitis B].

Chen XM, Liu ZM, Du XF, Yang ZG, Chen XM

Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences1 Mar 2005

PMID15812884 (opens in a new tab)DOI10.3785/j.issn.1008-9292.2005.02.006 (opens in a new tab)PepBankPUB-15812884
Publisher pagePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In ducks with duck hepatitis B, adding thymosin alpha1 to lamivudine reduced serum DHBV titre more than lamivudine alone.

    In plain wordsIn ducks with hepatitis B, adding thymosin alpha‑1 to lamivudine lowered virus levels more than lamivudine alone.

    Peptide
    Thymosin alpha-1
    Outcome
    DecreaseSerum DHBV titre
    Study

    duckn: not reported in source

    Peking ducks infected with duck hepatitis B virus
    Comparator
    Lamivudine alone
    Outcome group
    Antiviral activity · Infection
    Studied dose
    Dose not stated · 8 daysAs given in this study (duck).

    Source sentences

    Summary
    The serum DHBV titrate was significantly reduced (4483.2+/-5193.4 compared with 9351.8+/-5059.6) after lamivudine treatment, and it was reduced more significantly(1692.2+/-589.2) after combination treatment with Talpha1.
    2 context sentences
    Summary · context
    Peking ducks of 1 d old were challenged with DHBV-positive serum and used as a duck hepatitis B model.
    Summary · context
    After treated with lamivudine for three months, the ducks were randomly grouped and treated with or without Talpha1 for 8 d.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In ducks with duck hepatitis B, adding thymosin alpha1 to lamivudine increased liver inflammation degree compared with lamivudine alone.

    In plain wordsIn ducks with hepatitis B, adding thymosin alpha‑1 to lamivudine raised liver inflammation compared with lamivudine alone.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseLiver inflammation degree
    Study

    duckn: not reported in source

    Peking ducks infected with duck hepatitis B virus
    Comparator
    Lamivudine alone
    Outcome group
    Inflammation markers · Liver
    Studied dose
    Dose not stated · 8 daysAs given in this study (duck).

    Measurements

    Liver inflammation degree
    9 score
    lamivudine plus Talpha1
    Liver inflammation degree
    6.2 score
    lamivudine alone

    Source sentences

    Summary
    The combination treatment with Talpha1 increased liver inflammation degree (9.0+/-5.2).
    3 context sentences
    Summary · context
    Lamivudine reduced the degeneration degree of hepatocytes (3.2+/-0.8 compared with 4.6+/-0.5) and the inflammation degree of liver (6.2+/-3.3 compared with 8.6+/-2.8).
    Summary · context
    Peking ducks of 1 d old were challenged with DHBV-positive serum and used as a duck hepatitis B model.
    Summary · context
    After treated with lamivudine for three months, the ducks were randomly grouped and treated with or without Talpha1 for 8 d.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    12 Oct 2026, 17:28 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:02 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.